Two	O
distinct	O
signal	O
transmission	O
pathways	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
are	O
inhibited	O
by	O
complexes	O
formed	O
between	O
an	O
immunophilin	B-protein
and	O
either	O
FK506	O
or	O
rapamycin	O
.	O

Proliferation	O
and	O
immunologic	O
function	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
are	O
initiated	O
by	O
signals	O
from	O
the	O
antigen	B-protein
receptor	I-protein
that	O
are	O
inhibited	O
by	O
the	O
immunosuppressant	O
FK506	O
but	O
not	O
by	O
its	O
structural	O
analog	O
,	O
rapamycin	O
.	O

On	O
the	O
other	O
hand	O
,	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
-induced	O
signals	O
are	O
blocked	O
by	O
rapamycin	O
but	O
not	O
by	O
FK506	O
.	O

Remarkably	O
,	O
these	O
two	O
drugs	O
inhibit	O
each	O
other	O
's	O
actions	O
,	O
raising	O
the	O
possibility	O
that	O
both	O
act	O
by	O
means	O
of	O
a	O
common	O
immunophilin	B-protein
(	O
immunosuppressant	B-protein
binding	I-protein
protein	I-protein
)	O
.	O

We	O
find	O
that	O
the	O
dissociation	O
constant	O
of	O
rapamycin	O
to	O
the	O
FK506	B-protein
binding	I-protein
protein	I-protein
FKBP	B-protein
(	O
Kd	O
=	O
0.2	O
nM	O
)	O
is	O
close	O
to	O
the	O
dissociation	O
constant	O
of	O
FK506	O
to	O
FKBP	B-protein
(	O
Kd	O
=	O
0.4	O
nM	O
)	O
and	O
to	O
their	O
effective	O
biologic	O
inhibitory	O
concentrations	O
.	O

However	O
,	O
an	O
excess	O
of	O
rapamycin	O
is	O
needed	O
to	O
revert	O
FK506-mediated	O
inhibition	O
of	O
IL-2	B-protein
production	O
,	O
apoptosis	O
,	O
and	O
transcriptional	O
activation	O
of	O
NF-AT	B-protein
,	O
a	O
T-cell-specific	B-protein
transcription	I-protein
factor	I-protein
necessary	O
for	O
IL-2	B-DNA
gene	I-DNA
activation	O
.	O

Similarly	O
,	O
an	O
excess	O
of	O
FK506	O
is	O
needed	O
to	O
revert	O
rapamycin-mediated	O
inhibition	O
of	O
IL-2	B-protein
-induced	O
proliferation	O
.	O

The	O
drug	O
concentrations	O
required	O
for	O
antagonism	O
may	O
be	O
explained	O
by	O
the	O
relative	O
affinity	O
of	O
the	O
drugs	O
to	O
,	O
and	O
by	O
the	O
abundance	O
of	O
,	O
the	O
immunophilin	B-protein
FKBP	B-protein
.	O

FKBP	B-protein
has	O
been	O
shown	O
to	O
catalyze	O
the	O
interconversion	O
of	O
the	O
cis-	O
and	O
trans-rotamers	O
of	O
the	O
peptidyl-prolyl	B-protein
amide	I-protein
bond	I-protein
of	O
peptide	O
substrates	O
;	O
here	O
we	O
show	O
that	O
rapamycin	O
,	O
like	O
FK506	O
,	O
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
rotamase	O
activity	O
of	O
FKBP	B-protein
(	O
Ki	O
=	O
0.2	O
nM	O
)	O
.	O

Neither	O
FKBP	B-protein
binding	O
nor	O
inhibition	O
of	O
rotamase	O
activity	O
of	O
FKBP	B-protein
alone	O
is	O
sufficient	O
to	O
explain	O
the	O
biologic	O
actions	O
of	O
these	O
drugs	O
.	O

Rather	O
,	O
these	O
findings	O
suggest	O
that	O
immunophilin	B-protein
bound	O
to	O
FK506	O
interferes	O
with	O
antigen	B-protein
receptor	I-protein
-induced	O
signals	O
,	O
while	O
rapamycin	O
bound	O
to	O
the	O
immunophilin	B-protein
interferes	O
with	O
IL-2	B-protein
-induced	O
signals	O
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

87	NULL
,	NULL
pp	NULL
.	NULL

9231-9235	NULL
,	NULL
December	NULL
1990	NULL
Immunology	NULL
Two	NULL
distinct	NULL
signal	NULL
transmission	NULL
pathways	NULL
in	NULL
T	NULL
lymphocytes	NULL
are	NULL
inhibited	NULL
by	NULL
complexes	NULL
formed	NULL
between	NULL
an	NULL
immunophilin	NULL
and	NULL
either	NULL
FK506	NULL
or	NULL
rapamycin	NULL
(	NULL
cyclosporin	NULL
A/FK506	NULL
binding	NULL
protein	NULL
/rotamase	NULL
)	NULL
BARBARA	NULL
E.	NULL
Brerer*	NULL
``	NULL
}	NULL
§	NULL
,	NULL
Petri	NULL
S.	NULL
MatTIitLaA	NULL
``	NULL
,	NULL
Rosert	NULL
F	NULL
.	NULL

StanpaERT	NULL
!	NULL

!	NULL

,	NULL
Leonarp	NULL
A.	NULL
HerzeEnBERGNT	NULL
,	NULL
STEVEN	NULL
J	NULL
.	NULL

BuraAKOFF*T	NULL
!	NULL

,	NULL
GERALD	NULL
CRABTREE	NULL
!	NULL

,	NULL
anp	NULL
StuaRT	NULL
L.	NULL
Scureiser	NULL
!	NULL

*Division	NULL
of	NULL
Pediatric	NULL
Oncology	NULL
,	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
;	NULL
Hematology	NULL
Division	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Brigham	NULL
&	NULL
Women	NULL
's	NULL
Hospital	NULL
:	NULL
;	NULL
Departments	NULL
of	NULL
*Medicine	NULL
and	NULL
**Pediatrics	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02115	NULL
;	NULL
``	NULL
Beckman	NULL
Center	NULL
for	NULL
Molecular	NULL
and	NULL
Genetic	NULL
Medicine	NULL
,	NULL
Stanford	NULL
University	NULL
,	NULL
Stanford	NULL
,	NULL
CA	NULL
94305	NULL
;	NULL
and	NULL
'Department	NULL
of	NULL
Chemistry	NULL
,	NULL
Harvard	NULL
University	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
02138	NULL
Communicated	NULL
by	NULL
Samuel	NULL
J.	NULL
Danishefsky	NULL
,	NULL
August	NULL
13	NULL
,	NULL
1990	NULL
(	NULL
received	NULL
for	NULL
review	NULL
July	NULL
11	NULL
,	NULL
1990	NULL
)	NULL
ABSTRACT	NULL
Proliferation	NULL
and	NULL
immunologic	NULL
function	NULL
of	NULL
T	NULL
lymphocytes	NULL
are	NULL
initiated	NULL
by	NULL
signals	NULL
from	NULL
the	NULL
antigen	NULL
receptor	NULL
that	NULL
are	NULL
inhibited	NULL
by	NULL
the	NULL
immunosuppressant	NULL
FK506	NULL
but	NULL
not	NULL
by	NULL
its	NULL
structural	NULL
analog	NULL
,	NULL
rapamycin	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
-induced	NULL
signals	NULL
are	NULL
blocked	NULL
by	NULL
rapamycin	NULL
but	NULL
not	NULL
by	NULL
FK506	NULL
.	NULL

Remarkably	NULL
,	NULL
these	NULL
two	NULL
drugs	NULL
inhibit	NULL
each	NULL
other	NULL
's	NULL
actions	NULL
,	NULL
raising	NULL
the	NULL
possibility	NULL
that	NULL
both	NULL
act	NULL
by	NULL
means	NULL
of	NULL
a	NULL
common	NULL
immunophilin	NULL
(	NULL
immunosuppressant	NULL
binding	NULL
protein	NULL
)	NULL
.	NULL

We	NULL
find	NULL
that	NULL
the	NULL
dissociation	NULL
constant	NULL
of	NULL
rapamycin	NULL
to	NULL
the	NULL
FK506	NULL
binding	NULL
protein	NULL
FKBP	NULL
(	NULL
K	NULL
,	NULL
=	NULL
0.2	NULL
nM	NULL
)	NULL
is	NULL
close	NULL
to	NULL
the	NULL
dissociation	NULL
constant	NULL
of	NULL
FK506	NULL
to	NULL
FKBP	NULL
(	NULL
K	NULL
,	NULL
,	NULL
=	NULL
0.4	NULL
nM	NULL
)	NULL
and	NULL
to	NULL
their	NULL
effective	NULL
biologic	NULL
inhibitory	NULL
concentrations	NULL
.	NULL

However	NULL
,	NULL
an	NULL
excess	NULL
of	NULL
rapamycin	NULL
is	NULL
needed	NULL
to	NULL
revert	NULL
FK506-mediated	NULL
inhibition	NULL
of	NULL
IL-2	NULL
production	NULL
,	NULL
apoptosis	NULL
,	NULL
and	NULL
transcriptional	NULL
activation	NULL
of	NULL
NF-AT	NULL
,	NULL
a	NULL
T-cell-specific	NULL
transcription	NULL
factor	NULL
necessary	NULL
for	NULL
IL-2	NULL
gene	NULL
activation	NULL
.	NULL

Similarly	NULL
,	NULL
an	NULL
excess	NULL
of	NULL
FK506	NULL
is	NULL
needed	NULL
to	NULL
revert	NULL
rapamycin-mediated	NULL
inhibition	NULL
of	NULL
IL-2-induced	NULL
proliferation	NULL
.	NULL

The	NULL
drug	NULL
concentrations	NULL
required	NULL
for	NULL
antagonism	NULL
may	NULL
be	NULL
explained	NULL
by	NULL
the	NULL
relative	NULL
affinity	NULL
of	NULL
the	NULL
drugs	NULL
to	NULL
,	NULL
and	NULL
by	NULL
the	NULL
abundance	NULL
of	NULL
,	NULL
the	NULL
immunophilin	NULL
FKBP	NULL
.	NULL

FKBP	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
catalyze	NULL
the	NULL
interconversion	NULL
of	NULL
the	NULL
cis-and	NULL
trans-rotamers	NULL
of	NULL
the	NULL
peptidyl-prolyl	NULL
amide	NULL
bond	NULL
of	NULL
peptide	NULL
substrates	NULL
;	NULL
here	NULL
we	NULL
show	NULL
that	NULL
rapamycin	NULL
,	NULL
like	NULL
FK506	NULL
,	NULL
is	NULL
a	NULL
potent	NULL
inhibitor	NULL
of	NULL
the	NULL
rotamase	NULL
activity	NULL
of	NULL
FKBP	NULL
(	NULL
K	NULL
;	NULL
=	NULL
0.2	NULL
nM	NULL
)	NULL
.	NULL

Neither	NULL
FKBP	NULL
binding	NULL
nor	NULL
inhibition	NULL
of	NULL
rotamase	NULL
activity	NULL
of	NULL
FKBP	NULL
alone	NULL
is	NULL
sufficient	NULL
to	NULL
explain	NULL
the	NULL
biologic	NULL
actions	NULL
of	NULL
these	NULL
drugs	NULL
.	NULL

Rather	NULL
,	NULL
these	NULL
findings	NULL
suggest	NULL
that	NULL
immunophilin	NULL
bound	NULL
to	NULL
FK506	NULL
interferes	NULL
with	NULL
antigen	NULL
receptor-induced	NULL
sig-nals	NULL
,	NULL
while	NULL
rapamycin	NULL
bound	NULL
to	NULL
the	NULL
immunophilin	NULL
interferes	NULL
with	NULL
IL-2-induced	NULL
signals	NULL
.	NULL

Cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
and	NULL
the	NULL
structurally	NULL
unrelated	NULL
immunosuppressant	NULL
FK506	NULL
have	NULL
been	NULL
demonstrated	NULL
to	NULL
inhibit	NULL
T-cell	NULL
activation	NULL
and	NULL
to	NULL
be	NULL
effective	NULL
in	NULL
organ	NULL
transplantation	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

CsA	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
to	NULL
and	NULL
inhibit	NULL
the	NULL
rotamase	NULL
activity	NULL
of	NULL
a	NULL
cytoplasmic	NULL
enzyme	NULL
,	NULL
cyclophilin	NULL
(	NULL
CyP	NULL
)	NULL
(	NULL
4-6	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
a	NULL
cytoplasmic	NULL
receptor	NULL
for	NULL
FK	NULL
506	NULL
,	NULL
FK506	NULL
binding	NULL
protein	NULL
(	NULL
FKBP	NULL
)	NULL
,	NULL
which	NULL
is	NULL
unrelated	NULL
in	NULL
sequence	NULL
to	NULL
CyP	NULL
,	NULL
has	NULL
also	NULL
been	NULL
shown	NULL
to	NULL
have	NULL
similar	NULL
rotamase	NULL
activity	NULL
,	NULL
suggesting	NULL
that	NULL
this	NULL
common	NULL
enzymatic	NULL
property	NULL
of	NULL
immunophilin	NULL
proteins	NULL
(	NULL
immunosuppressant	NULL
binding	NULL
proteins	NULL
)	NULL
may	NULL
be	NULL
related	NULL
to	NULL
the	NULL
regulation	NULL
of	NULL
T-cell	NULL
activation	NULL
(	NULL
7-10	NULL
)	NULL
.	NULL

Rapamycin	NULL
is	NULL
a	NULL
macrolide	NULL
similar	NULL
in	NULL
structure	NULL
to	NULL
FK506	NULL
and	NULL
,	NULL
like	NULL
FK506	NULL
,	NULL
inhibits	NULL
T-cell	NULL
proliferation	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
and	NULL
binds	NULL
to	NULL
FKBP	NULL
.	NULL

Recently	NULL
,	NULL
rapamycin	NULL
and	NULL
FK506	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
inhibit	NULL
each	NULL
other	NULL
's	NULL
actions	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

Here	NULL
we	NULL
confirm	NULL
and	NULL
extend	NULL
those	NULL
findings	NULL
by	NULL
examining	NULL
a	NULL
number	NULL
of	NULL
specific	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

$	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

9231	NULL
actions	NULL
of	NULL
these	NULL
drugs	NULL
.	NULL

Our	NULL
results	NULL
suggest	NULL
that	NULL
a	NULL
common	NULL
drug	NULL
receptor	NULL
binding	NULL
site	NULL
is	NULL
involved	NULL
in	NULL
at	NULL
least	NULL
two	NULL
distinct	NULL
signaling	NULL
pathways	NULL
in	NULL
the	NULL
T-cell	NULL
activation	NULL
cascade	NULL
.	NULL

Both	NULL
rapamycin	NULL
(	NULL
K	NULL
,	NULL
0.2	NULL
nM	NULL
)	NULL
and	NULL
FK506	NULL
(	NULL
Kq	NULL
0.4	NULL
nM	NULL
)	NULL
are	NULL
shown	NULL
to	NULL
bind	NULL
with	NULL
high	NULL
affinity	NULL
to	NULL
FKBP	NULL
.	NULL

Thus	NULL
,	NULL
FKBP	NULL
is	NULL
possibly	NULL
involved	NULL
in	NULL
one	NULL
or	NULL
both	NULL
of	NULL
the	NULL
aforementioned	NULL
pathways	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
both	NULL
rapamycin	NULL
(	NULL
K	NULL
;	NULL
=	NULL
0.2	NULL
nM	NULL
)	NULL
and	NULL
FK506	NULL
(	NULL
K	NULL
;	NULL
=	NULL
1.7	NULL
nM	NULL
;	NULL
ref	NULL
.	NULL

14	NULL
)	NULL
are	NULL
shown	NULL
to	NULL
be	NULL
inhibitors	NULL
of	NULL
the	NULL
rotamase	NULL
activity	NULL
of	NULL
FKBP	NULL
.	NULL

Accordingly	NULL
,	NULL
the	NULL
inhibition	NULL
of	NULL
the	NULL
rotamase	NULL
activity	NULL
of	NULL
FKBP	NULL
,	NULL
assayed	NULL
in	NULL
vitro	NULL
with	NULL
synthetic	NULL
substrates	NULL
,	NULL
is	NULL
apparently	NULL
an	NULL
insufficient	NULL
requirement	NULL
for	NULL
mediating	NULL
the	NULL
biological	NULL
effects	NULL
of	NULL
either	NULL
rapamycin	NULL
or	NULL
FK506	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Reagents	NULL
,	NULL
Cell	NULL
Culture	NULL
,	NULL
Interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
Production	NULL
,	NULL
and	NULL
DNA	NULL
Fragmentation	NULL
.	NULL

The	NULL
IL-2-producing	NULL
murine	NULL
T-cell	NULL
hybridoma	NULL
16.CD2-15.20	NULL
(	NULL
15	NULL
)	NULL
was	NULL
cultured	NULL
(	NULL
10°	NULL
cells	NULL
per	NULL
well	NULL
)	NULL
with	NULL
or	NULL
without	NULL
a	NULL
2	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
culture	NULL
supernatant	NULL
of	NULL
the	NULL
anti-murine	NULL
CD3	NULL
monoclonal	NULL
antibody	NULL
(	NULL
mAb	NULL
)	NULL
145-2C11	NULL
(	NULL
16	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
CsA	NULL
,	NULL
FK	NULL
506	NULL
,	NULL
or	NULL
rapamycin	NULL
.	NULL

At	NULL
24	NULL
hr	NULL
,	NULL
culture	NULL
supernatants	NULL
were	NULL
dialyzed	NULL
and	NULL
assayed	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
IL-2	NULL
as	NULL
described	NULL
(	NULL
15	NULL
)	NULL
.	NULL

DNA	NULL
was	NULL
isolated	NULL
from	NULL
the	NULL
cells	NULL
and	NULL
assayed	NULL
for	NULL
induction	NULL
of	NULL
DNA	NULL
fragmentation	NULL
or	NULL
apoptosis	NULL
on	NULL
an	NULL
ethidium	NULL
bromide-stained	NULL
2	NULL
%	NULL
agarose	NULL
gel	NULL
as	NULL
described	NULL
by	NULL
Shi	NULL
et	NULL
al	NULL
.	NULL

(	NULL
17	NULL
)	NULL
.	NULL

NFAT-Gal	NULL
Plasmid	NULL
and	NULL
Transfection	NULL
into	NULL
Jurkat	NULL
Cells	NULL
.	NULL

The	NULL
NFAT-Gal	NULL
plasmid	NULL
and	NULL
Jurkat	NULL
cell	NULL
line	NULL
stably	NULL
transfected	NULL
with	NULL
the	NULL
plasmid	NULL
were	NULL
described	NULL
by	NULL
Fiering	NULL
et	NULL
al	NULL
.	NULL

(	NULL
18	NULL
)	NULL
.	NULL

The	NULL
plasmid	NULL
contains	NULL
the	NULL
Escherichia	NULL
coli	NULL
lacZ	NULL
gene	NULL
attached	NULL
to	NULL
a	NULL
minimal	NULL
promoter	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
(	NULL
-72	NULL
to	NULL
+47	NULL
)	NULL
,	NULL
linked	NULL
to	NULL
a	NULL
trimer	NULL
of	NULL
the	NULL
NF-AT	NULL
(	NULL
a	NULL
T-cell-specific	NULL
transcription	NULL
factor	NULL
)	NULL
binding	NULL
site	NULL
(	NULL
-286	NULL
to	NULL
-257	NULL
of	NULL
IL-2	NULL
)	NULL
,	NULL
and	NULL
a	NULL
hygromycin-resistance	NULL
gene	NULL
linked	NULL
to	NULL
thymidine	NULL
kinase	NULL
enhancer	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

Twenty	NULL
micrograms	NULL
of	NULL
linearized	NULL
plasmid	NULL
was	NULL
electro-porated	NULL
into	NULL
Jurkat	NULL
cells	NULL
(	NULL
250	NULL
V	NULL
and	NULL
960	NULL
uF	NULL
of	NULL
electric	NULL
shock	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
RPMI	NULL
1640	NULL
)	NULL
,	NULL
and	NULL
stable	NULL
transfectants	NULL
were	NULL
established	NULL
after	NULL
hygromycin	NULL
selection	NULL
.	NULL

Clones	NULL
that	NULL
expressed	NULL
the	NULL
highest	NULL
B-galactosidase	NULL
activity	NULL
upon	NULL
stimulation	NULL
were	NULL
selected	NULL
using	NULL
the	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
and	NULL
the	NULL
fluorogenic	NULL
substrate	NULL
fluorescein	NULL
di-B-p-galactoside	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
.	NULL

Ribonuclease	NULL
protection	NULL
assays	NULL
were	NULL
performed	NULL
by	NULL
using	NULL
the	NULL
template	NULL
described	NULL
by	NULL
Verweij	NULL
et	NULL
al	NULL
.	NULL

(	NULL
20	NULL
)	NULL
as	NULL
described	NULL
by	NULL
Melton	NULL
et	NULL
al	NULL
.	NULL

(	NULL
21	NULL
)	NULL
.	NULL

Abbreviations	NULL
:	NULL
CsA	NULL
,	NULL
cyclosporin	NULL
A	NULL
;	NULL
CyP	NULL
,	NULL
cyclophilin	NULL
;	NULL
FKBP	NULL
,	NULL
FK506	NULL
binding	NULL
protein	NULL
;	NULL
IL-2	NULL
,	NULL
interleukin	NULL
2	NULL
;	NULL
mAb	NULL
,	NULL
monoclonal	NULL
anti-body	NULL
.	NULL

$	NULL
To	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
at	NULL
:	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
Room	NULL
1610B	NULL
,	NULL
44	NULL
Binney	NULL
Street	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02115	NULL
.	NULL

9232	NULL
Immunology	NULL
:	NULL
Bierer	NULL
et	NULL
al	NULL
.	NULL

Measurement	NULL
of	NULL
B-Galactosidase	NULL
Activity	NULL
,	NULL
Nuclear	NULL
Extracts	NULL
,	NULL
and	NULL
DNA	NULL
Binding	NULL
Studies	NULL
.	NULL

B-Galactosidase	NULL
activity	NULL
was	NULL
measured	NULL
from	NULL
the	NULL
fluorescence	NULL
of	NULL
4-methylumbelliferyl	NULL
B-p-galactoside	NULL
(	NULL
Sigma	NULL
)	NULL
cleaved	NULL
at	NULL
the	NULL
B-galactosidase	NULL
bond	NULL
.	NULL

Fifty	NULL
thousand	NULL
cells	NULL
were	NULL
stimulated	NULL
in	NULL
200	NULL
ul	NULL
of	NULL
fresh	NULL
culture	NULL
medium	NULL
and	NULL
centrifuged	NULL
;	NULL
the	NULL
supernatant	NULL
was	NULL
removed	NULL
;	NULL
and	NULL
180	NULL
ul	NULL
of	NULL
reaction	NULL
medium	NULL
(	NULL
100	NULL
mM	NULL
Na	NULL
;	NULL
HPO4	NULL
,	NULL
pH	NULL
7.0/10	NULL
mM	NULL
KCIl/1	NULL
mM	NULL
Mg	NULL
$	NULL
O	NULL
,	NULL
/0.1	NULL
%	NULL
Triton	NULL
X-100/0.5	NULL
mM	NULL
4-methylumbelliferyl	NULL
B-p-galactoside	NULL
)	NULL
was	NULL
added	NULL
.	NULL

After	NULL
1	NULL
hr	NULL
at	NULL
20°C	NULL
the	NULL
reaction	NULL
was	NULL
stopped	NULL
by	NULL
adding	NULL
75	NULL
pl	NULL
of	NULL
stop	NULL
buffer	NULL
(	NULL
300	NULL
mM	NULL
glycine/15	NULL
mM	NULL
EDTA	NULL
,	NULL
pH	NULL
11.3	NULL
)	NULL
,	NULL
and	NULL
fluorescence	NULL
at	NULL
460	NULL
nm	NULL
was	NULL
measured	NULL
by	NULL
using	NULL
355-nm	NULL
excitation	NULL
with	NULL
a	NULL
Titertek	NULL
Fluoroscan	NULL
II	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
made	NULL
as	NULL
described	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Protein	NULL
samples	NULL
were	NULL
desalted	NULL
by	NULL
passage	NULL
over	NULL
a	NULL
Bio-Gel	NULL
P-6DG	NULL
column	NULL
(	NULL
Bio-Rad	NULL
)	NULL
at	NULL
4°C	NULL
.	NULL

Protein	NULL
concentrations	NULL
were	NULL
determined	NULL
by	NULL
the	NULL
Bradford	NULL
assay	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
24	NULL
,	NULL
25	NULL
)	NULL
with	NULL
the	NULL
sequences	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
as	NULL
probe	NULL
for	NULL
NF-AT	NULL
and	NULL
10	NULL
ug	NULL
of	NULL
protein	NULL
.	NULL

Competitive	NULL
Binding	NULL
to	NULL
FKBP	NULL
.	NULL

Assays	NULL
by	NULL
the	NULL
Sephadex	NULL
LH-20	NULL
method	NULL
(	NULL
4	NULL
)	NULL
measured	NULL
the	NULL
displacement	NULL
of	NULL
{	NULL
*H	NULL
]	NULL
dihy-droFK506	NULL
from	NULL
recombinant	NULL
human	NULL
FKBP	NULL
(	NULL
9	NULL
)	NULL
by	NULL
dihy-droFK506	NULL
,	NULL
rapamycin	NULL
,	NULL
and	NULL
FK506	NULL
.	NULL

Protein	NULL
(	NULL
1	NULL
nM	NULL
)	NULL
,	NULL
labeled	NULL
drug	NULL
(	NULL
0.5	NULL
nM	NULL
)	NULL
,	NULL
and	NULL
competitor	NULL
were	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
in	NULL
110	NULL
ul	NULL
of	NULL
buffer	NULL
(	NULL
100	NULL
mM	NULL
NaCIl/20	NULL
mM	NULL
phosphate/l1	NULL
mM	NULL
EDTA	NULL
,	NULL
pH	NULL
7.3	NULL
)	NULL
to	NULL
which	NULL
0.015	NULL
%	NULL
Triton	NULL
X-100	NULL
was	NULL
added	NULL
.	NULL

The	NULL
bound	NULL
fraction	NULL
was	NULL
isolated	NULL
by	NULL
chromatography	NULL
of	NULL
50	NULL
ul	NULL
of	NULL
the	NULL
mixture	NULL
on	NULL
a	NULL
1.5-ml	NULL
column	NULL
by	NULL
Sephadex	NULL
LH-20	NULL
(	NULL
Pharmacia	NULL
)	NULL
.	NULL

This	NULL
sample	NULL
and	NULL
50	NULL
ul	NULL
of	NULL
assay	NULL
mixture	NULL
were	NULL
assayed	NULL
by	NULL
scintillation	NULL
spectrometry	NULL
to	NULL
obtain	NULL
the	NULL
bound	NULL
and	NULL
total	NULL
concentrations	NULL
,	NULL
respectively	NULL
.	NULL

Binding	NULL
data	NULL
were	NULL
analyzed	NULL
with	NULL
the	NULL
program	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Rotamase	NULL
Activity	NULL
and	NULL
Inhibition	NULL
Studies	NULL
.	NULL

The	NULL
assay	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
6	NULL
)	NULL
with	NULL
the	NULL
test	NULL
peptide	NULL
succinyl-Ala-Leu-Pro-Phe-p-nitroanilide	NULL
(	NULL
14	NULL
,	NULL
27	NULL
)	NULL
(	NULL
Bachem	NULL
)	NULL
and	NULL
recombinant	NULL
human	NULL
FKBP	NULL
.	NULL

A	NULL
3.5-ml	NULL
cuvette	NULL
was	NULL
charged	NULL
with	NULL
1.4	NULL
ml	NULL
of	NULL
test	NULL
peptide	NULL
(	NULL
55	NULL
uM	NULL
)	NULL
in	NULL
40	NULL
mM	NULL
Hepes	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
plus	NULL
0.015	NULL
%	NULL
Triton	NULL
X-100	NULL
.	NULL

Stirring	NULL
was	NULL
begun	NULL
and	NULL
FKBP	NULL
(	NULL
5.0	NULL
Ll	NULL
of	NULL
a	NULL
10.8	NULL
uM	NULL
solution	NULL
)	NULL
and	NULL
rapamycin	NULL
solution	NULL
{	NULL
in	NULL
25	NULL
l	NULL
of	NULL
50	NULL
%	NULL
Antl-CD3	NULL
MAb	NULL
0	NULL
100	NULL
200	NULL
300	NULL
400	NULL
500	NULL
IL-2	NULL
Production	NULL
(	NULL
U/ml	NULL
)	NULL
Antl-CD3	NULL
MAb	NULL
0	NULL
100	NULL
200	NULL
300	NULL
IL-2	NULL
Production	NULL
-	NULL
(	NULL
U/mi	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87	NULL
(	NULL
1990	NULL
)	NULL
(	NULL
vol/vol	NULL
)	NULL
methanol	NULL
]	NULL
were	NULL
added	NULL
.	NULL

a-Chymotrypsin	NULL
was	NULL
added	NULL
(	NULL
75	NULL
ul	NULL
of	NULL
10	NULL
mg/ml	NULL
in	NULL
1	NULL
mM	NULL
HCI	NULL
)	NULL
and	NULL
the	NULL
(	NULL
p-nitroaniline	NULL
)	NULL
was	NULL
monitored	NULL
;	NULL
data	NULL
were	NULL
collected	NULL
every	NULL
0.5	NULL
s.	NULL
The	NULL
temperature	NULL
was	NULL
maintained	NULL
at	NULL
10.0	NULL
+	NULL
0.1°C	NULL
.	NULL

First-order	NULL
rate	NULL
constants	NULL
were	NULL
calculated	NULL
by	NULL
using	NULL
the	NULL
Kore	NULL
program	NULL
(	NULL
28	NULL
)	NULL
.	NULL

The	NULL
data	NULL
were	NULL
fit	NULL
to	NULL
a	NULL
tight-binding	NULL
inhibitor	NULL
model	NULL
(	NULL
29	NULL
)	NULL
,	NULL
from	NULL
which	NULL
the	NULL
K	NULL
;	NULL
of	NULL
0.2	NULL
nM	NULL
and	NULL
the	NULL
FKBP	NULL
concentration	NULL
of	NULL
36	NULL
nM	NULL
were	NULL
derived	NULL
.	NULL

RESULTS	NULL
We	NULL
have	NULL
used	NULL
a	NULL
murine	NULL
T-cell	NULL
hybridoma	NULL
as	NULL
a	NULL
model	NULL
of	NULL
antigen-specific	NULL
T-cell	NULL
activation	NULL
.	NULL

The	NULL
murine	NULL
T-cell	NULL
hybridoma	NULL
16.CD2-15.20	NULL
can	NULL
be	NULL
activated	NULL
to	NULL
produce	NULL
IL-2	NULL
by	NULL
means	NULL
of	NULL
the	NULL
cell	NULL
surface	NULL
T-cell	NULL
receptor-CD3	NULL
complex	NULL
either	NULL
by	NULL
antigen	NULL
or	NULL
by	NULL
mAb	NULL
directed	NULL
against	NULL
CD3	NULL
(	NULL
anti-CD3	NULL
)	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Also	NULL
,	NULL
upon	NULL
stimulation	NULL
there	NULL
is	NULL
a	NULL
diminution	NULL
of	NULL
the	NULL
prolifer-ative	NULL
rate	NULL
as	NULL
well	NULL
as	NULL
nuclear	NULL
lobulation	NULL
,	NULL
DNA	NULL
fragmentation	NULL
,	NULL
and	NULL
cell	NULL
death	NULL
by	NULL
apoptosis	NULL
(	NULL
17	NULL
,	NULL
30	NULL
)	NULL
.	NULL

We	NULL
have	NULL
assessed	NULL
the	NULL
effect	NULL
of	NULL
FK506	NULL
and	NULL
rapamycin	NULL
on	NULL
the	NULL
functional	NULL
properties	NULL
of	NULL
this	NULL
T-cell	NULL
hybridoma	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
the	NULL
murine	NULL
T-cell	NULL
hybridoma	NULL
to	NULL
produce	NULL
IL-2	NULL
upon	NULL
stimulation	NULL
with	NULL
anti-CD3	NULL
was	NULL
inhibited	NULL
by	NULL
FK	NULL
506	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
in	NULL
a	NULL
concentration-dependent	NULL
fashion	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
has	NULL
been	NULL
observed	NULL
in	NULL
other	NULL
systems	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
,	NULL
FK506	NULL
was	NULL
10-	NULL
to	NULL
100-fold	NULL
more	NULL
effective	NULL
than	NULL
CsA	NULL
in	NULL
inhibiting	NULL
IL-2	NULL
production	NULL
.	NULL

Rapamycin	NULL
,	NULL
structurally	NULL
related	NULL
to	NULL
FK506	NULL
,	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
act	NULL
as	NULL
an	NULL
immunosuppressant	NULL
and	NULL
to	NULL
inhibit	NULL
T-cell	NULL
proliferation	NULL
(	NULL
11-13	NULL
)	NULL
.	NULL

However	NULL
,	NULL
anti-CD3-induced	NULL
IL-2	NULL
production	NULL
by	NULL
the	NULL
hybridoma	NULL
was	NULL
not	NULL
significantly	NULL
inhibited	NULL
by	NULL
rapamycin	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

Incubation	NULL
with	NULL
anti-CD3	NULL
decreased	NULL
the	NULL
rate	NULL
of	NULL
proliferation	NULL
of	NULL
the	NULL
hybridoma	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
induced	NULL
apoptosis	NULL
or	NULL
DNA	NULL
fragmentation	NULL
to	NULL
characteristic	NULL
multimers	NULL
of	NULL
180	NULL
base	NULL
pairs	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
1	NULL
nM	NULL
FK506	NULL
at	NULL
the	NULL
initiation	NULL
of	NULL
culture	NULL
completely	NULL
prevented	NULL
the	NULL
induction	NULL
of	NULL
apoptosis	NULL
.	NULL

However	NULL
,	NULL
rapamycin	NULL
,	NULL
even	NULL
at	NULL
100-fold	NULL
higher	NULL
concentrations	NULL
,	NULL
did	NULL
not	NULL
prevent	NULL
IL-2	NULL
production	NULL
or	NULL
activation-induced	NULL
cell	NULL
death	NULL
.	NULL

Fig.1	NULL
.	NULL

EffectofFK506andrapa-mycin	NULL
on	NULL
IL-2	NULL
production	NULL
(	NULL
4	NULL
and	NULL
C	NULL
)	NULL
and	NULL
activation-induced	NULL
cell	NULL
death	NULL
(	NULL
B	NULL
and	NULL
D	NULL
)	NULL
.	NULL

The	NULL
murine	NULL
T-cell	NULL
hybridoma	NULL
16.CD2-15.20	NULL
(	NULL
15	NULL
)	NULL
was	NULL
cultured	NULL
with	NULL
the	NULL
anti-murine	NULL
CD3	NULL
mAb	NULL
145-2C11	NULL
(	NULL
16	NULL
)	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
10	NULL
nM	NULL
CsA	NULL
,	NULL
1	NULL
nM	NULL
FK506	NULL
,	NULL
or	NULL
100	NULL
nM	NULL
rapamycin	NULL
(	NULL
RAP	NULL
)	NULL
except	NULL
as	NULL
indicated	NULL
.	NULL

At	NULL
24	NULL
hr	NULL
,	NULL
dialyzed	NULL
culture	NULL
supernatants	NULL
were	NULL
harvested	NULL
and	NULL
assessed	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
IL-2	NULL
by	NULL
their	NULL
ability	NULL
to	NULL
support	NULL
the	NULL
proliferation	NULL
of	NULL
an	NULL
IL-2-dependent	NULL
murine	NULL
T-cell	NULL
line	NULL
,	NULL
CTLL-20	NULL
(	NULL
A	NULL
and	NULL
C	NULL
)	NULL
;	NULL
remaining	NULL
cells	NULL
were	NULL
assessed	NULL
for	NULL
induction	NULL
of	NULL
DNA	NULL
fragmentation	NULL
or	NULL
apoptosis	NULL
on	NULL
an	NULL
ethidium	NULL
bromide-stained	NULL
2	NULL
%	NULL
agarose	NULL
gel	NULL
(	NULL
B	NULL
and	NULL
D	NULL
)	NULL
.	NULL

Anti-Thy	NULL
1	NULL
and	NULL
anti-CD3	NULL
mAb	NULL
were	NULL
used	NULL
at	NULL
2	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
culture	NULL
supernatant	NULL
.	NULL

Immunology	NULL
:	NULL
Bierer	NULL
et	NULL
al	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
rapamycin	NULL
at	NULL
a	NULL
100-fold	NULL
excess	NULL
concentration	NULL
effectively	NULL
inhibited	NULL
the	NULL
ability	NULL
of	NULL
FK506	NULL
to	NULL
prevent	NULL
activation-induced	NULL
cell	NULL
death	NULL
(	NULL
Fig	NULL
.	NULL

1D	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
rapamycin	NULL
effectively	NULL
reversed	NULL
FK506-mediated	NULL
inhibition	NULL
of	NULL
IL-2	NULL
production	NULL
by	NULL
the	NULL
hybridoma	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
rapamycin	NULL
itself	NULL
did	NULL
not	NULL
affect	NULL
T-cell	NULL
receptor-CD3-mediated	NULL
signal	NULL
transduction	NULL
but	NULL
did	NULL
reverse	NULL
the	NULL
effect	NULL
of	NULL
FK506	NULL
upon	NULL
this	NULL
pathway	NULL
.	NULL

Recent	NULL
evidence	NULL
indicates	NULL
that	NULL
the	NULL
IL-2	NULL
gene	NULL
is	NULL
under	NULL
the	NULL
control	NULL
of	NULL
a	NULL
T-cell-specific	NULL
transcription	NULL
factor	NULL
(	NULL
NF-AT	NULL
)	NULL
that	NULL
is	NULL
activated	NULL
after	NULL
antigen	NULL
receptor	NULL
stimulation	NULL
of	NULL
T	NULL
cells	NULL
(	NULL
33	NULL
)	NULL
.	NULL

Although	NULL
other	NULL
transcription	NULL
factors	NULL
bind	NULL
to	NULL
the	NULL
IL-2	NULL
enhancer	NULL
(	NULL
34-36	NULL
)	NULL
,	NULL
they	NULL
are	NULL
expressed	NULL
in	NULL
many	NULL
cell	NULL
types	NULL
or	NULL
are	NULL
activated	NULL
without	NULL
a	NULL
requirement	NULL
for	NULL
protein	NULL
synthesis	NULL
.	NULL

Since	NULL
IL-2	NULL
gene	NULL
activation	NULL
requires	NULL
protein	NULL
synthesis	NULL
and	NULL
occurs	NULL
only	NULL
in	NULL
T	NULL
lymphocytes	NULL
,	NULL
NF-AT	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
one	NULL
protein	NULL
that	NULL
gives	NULL
rise	NULL
to	NULL
the	NULL
restricted	NULL
expression	NULL
of	NULL
IL-2	NULL
.	NULL

We	NULL
investigated	NULL
the	NULL
effects	NULL
of	NULL
FK506	NULL
and	NULL
rapamycin	NULL
on	NULL
NF-AT-dependent	NULL
transcription	NULL
by	NULL
assaying	NULL
B-galactosidase	NULL
mRNA	NULL
expression	NULL
and	NULL
enzymatic	NULL
activity	NULL
in	NULL
a	NULL
human	NULL
T-cell	NULL
leukemia	NULL
Jurkat	NULL
cell	NULL
clone	NULL
stably	NULL
transfected	NULL
with	NULL
a	NULL
construct	NULL
in	NULL
which	NULL
a	NULL
trimer	NULL
of	NULL
the	NULL
30-base-pair	NULL
NF-AT	NULL
binding	NULL
site	NULL
directs	NULL
transcription	NULL
of	NULL
the	NULL
B-galactosidase	NULL
gene	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

FK506	NULL
completely	NULL
inhibited	NULL
B-galactosidase	NULL
mRNA	NULL
expression	NULL
at	NULL
1.2	NULL
nM	NULL
,	NULL
and	NULL
rapamycin	NULL
(	NULL
550	NULL
nM	NULL
)	NULL
was	NULL
able	NULL
to	NULL
completely	NULL
reverse	NULL
the	NULL
effects	NULL
of	NULL
1.2	NULL
nM	NULL
FK506	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
rapamycin	NULL
with	NULL
various	NULL
concentrations	NULL
of	NULL
FK506	NULL
provided	NULL
a	NULL
dose-dependent	NULL
shift	NULL
of	NULL
the	NULL
FK506	NULL
dose-response	NULL
curve	NULL
in	NULL
which	NULL
a	NULL
10-fold	NULL
change	NULL
in	NULL
the	NULL
con	NULL
C	NULL
§	NULL
g	NULL
beta-galactosidase	NULL
activity	NULL
-	NULL
5	NULL
&	NULL
B	NULL
$	NULL
3	NULL
x	NULL
NF-AT	NULL
B	NULL
Galactosidase	NULL
NF-AT	NULL
Gal	NULL
Fusion	NULL
Gene	NULL
Q	NULL
«	NULL
gms	NULL
.	NULL

NF-AT/Gal	NULL
Transcript	NULL
Endogenous	NULL
IL-2	NULL
Transcript	NULL
a	NULL
a	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87	NULL
(	NULL
1990	NULL
)	NULL
9233	NULL
centration	NULL
of	NULL
rapamycin	NULL
produced	NULL
a	NULL
10-fold	NULL
reduction	NULL
in	NULL
the	NULL
sensitivity	NULL
to	NULL
FK506	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

At	NULL
the	NULL
50	NULL
%	NULL
inhibition	NULL
level	NULL
,	NULL
~300-fold	NULL
more	NULL
rapamycin	NULL
,	NULL
compared	NULL
to	NULL
FK506	NULL
,	NULL
was	NULL
required	NULL
to	NULL
reverse	NULL
the	NULL
effect	NULL
of	NULL
FK506	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

Rapamycin	NULL
alone	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
B-galactosidase	NULL
expression	NULL
at	NULL
concentrations	NULL
up	NULL
to	NULL
1.1	NULL
uM	NULL
.	NULL

FK506	NULL
(	NULL
1.2	NULL
nM	NULL
)	NULL
reduced	NULL
the	NULL
induction	NULL
of	NULL
NF-AT	NULL
binding	NULL
activity	NULL
by	NULL
about	NULL
10-fold	NULL
(	NULL
Fig	NULL
.	NULL

2D	NULL
)	NULL
,	NULL
which	NULL
is	NULL
substantially	NULL
less	NULL
than	NULL
the	NULL
1000-fold	NULL
or	NULL
more	NULL
reduction	NULL
in	NULL
transcriptional	NULL
activity	NULL
of	NULL
this	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

Rapamycin	NULL
was	NULL
able	NULL
to	NULL
overcome	NULL
completely	NULL
the	NULL
reduction	NULL
in	NULL
NF-AT	NULL
binding	NULL
activity	NULL
produced	NULL
by	NULL
FK506	NULL
(	NULL
Fig	NULL
.	NULL

2D	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
FK506	NULL
is	NULL
more	NULL
marked	NULL
on	NULL
IL-2	NULL
transcription	NULL
than	NULL
on	NULL
NF-AT	NULL
binding	NULL
.	NULL

CsA	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
block	NULL
completely	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
NF-AT	NULL
and	NULL
to	NULL
block	NULL
partially	NULL
the	NULL
development	NULL
of	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Unlike	NULL
its	NULL
effects	NULL
on	NULL
FK506	NULL
,	NULL
rapamycin	NULL
was	NULL
not	NULL
able	NULL
to	NULL
reverse	NULL
the	NULL
effects	NULL
of	NULL
CsA	NULL
on	NULL
NF-AT-dependent	NULL
transcription	NULL
or	NULL
the	NULL
reduction	NULL
of	NULL
NF-AT	NULL
binding	NULL
activity	NULL
seen	NULL
with	NULL
CsA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Rapamycin	NULL
,	NULL
but	NULL
not	NULL
FK506	NULL
,	NULL
inhibited	NULL
IL-2-driven	NULL
proliferation	NULL
of	NULL
a	NULL
cloned	NULL
,	NULL
IL-2-dependent	NULL
T-cell	NULL
line	NULL
,	NULL
CTLL-20	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
,	NULL
compared	NULL
to	NULL
FK506	NULL
,	NULL
rapamycin	NULL
has	NULL
a	NULL
different	NULL
inhibitory	NULL
effect	NULL
on	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
FK506	NULL
at	NULL
100-fold	NULL
excess	NULL
concentrations	NULL
to	NULL
rapamycin-treated	NULL
cultures	NULL
of	NULL
CTLL-20	NULL
restored	NULL
T-cell	NULL
proliferation	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
,	NULL
supporting	NULL
a	NULL
distinct	NULL
,	NULL
and	NULL
separable	NULL
,	NULL
spectrum	NULL
of	NULL
action	NULL
for	NULL
rapamycin	NULL
and	NULL
FK506	NULL
and	NULL
suggesting	NULL
that	NULL
the	NULL
basis	NULL
of	NULL
immunosuppression	NULL
by	NULL
FK506	NULL
and	NULL
rapamycin	NULL
differ	NULL
.	NULL

The	NULL
mutual	NULL
inhibition	NULL
of	NULL
FK506	NULL
and	NULL
rapamycin	NULL
suggests	NULL
the	NULL
existence	NULL
of	NULL
a	NULL
common	NULL
receptor	NULL
binding	NULL
site	NULL
.	NULL

Recently	NULL
,	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Production	NULL
of	NULL
the	NULL
NFAT-Gal	NULL
construct	NULL
.	NULL

The	NULL
putative	NULL
binding	NULL
protein	NULL
sites	NULL
on	NULL
the	NULL
IL-2	NULL
gene	NULL
are	NULL
noted	NULL
.	NULL

The	NULL
NFAT-Gal	NULL
construct	NULL
contains	NULL
E.	NULL
coli	NULL
lacZ	NULL
attached	NULL
to	NULL
the	NULL
IL-2	NULL
gene	NULL
at	NULL
position	NULL
+47	NULL
.	NULL

The	NULL
promoter	NULL
is	NULL
the	NULL
fragment	NULL
of	NULL
IL-2	NULL
from	NULL
-72	NULL
to	NULL
+47	NULL
,	NULL
which	NULL
contains	NULL
a	NULL
TATA	NULL
box	NULL
.	NULL

A	NULL
trimer	NULL
of	NULL
the	NULL
NF-AT	NULL
binding	NULL
site	NULL
(	NULL
-286	NULL
to	NULL
-257	NULL
of	NULL
IL-2	NULL
)	NULL
,	NULL
oriented	NULL
5	NULL
'	NULL
to	NULL
3	NULL
'	NULL
,	NULL
is	NULL
ligated	NULL
to	NULL
the	NULL
IL-2	NULL
promoter	NULL
at	NULL
-72	NULL
.	NULL

Lowercase	NULL
letters	NULL
in	NULL
the	NULL
NF-AT	NULL
sequences	NULL
are	NULL
bases	NULL
where	NULL
methyl-ation	NULL
inhibits	NULL
DNA	NULL
binding	NULL
.	NULL

(	NULL
B	NULL
)	NULL
FK506	NULL
inhibits	NULL
transcriptional	NULL
activity	NULL
of	NULL
NF-AT	NULL
and	NULL
transcription	NULL
of	NULL
IL-2	NULL
mRNA	NULL
,	NULL
whereas	NULL
rapamycin	NULL
reverses	NULL
the	NULL
effects	NULL
of	NULL
FK506	NULL
.	NULL

Qﬁ	NULL
Transcription	NULL
of	NULL
B-galactosidase	NULL
mRNA	NULL
&	NULL
4	NULL
from	NULL
the	NULL
NFAT-Gal	NULL
construct	NULL
was	NULL
measured	NULL
&	NULL
f	NULL
by	NULL
a	NULL
ribonuclease	NULL
assay	NULL
.	NULL

Transcripts	NULL
from	NULL
the	NULL
endogenous	NULL
IL-2	NULL
gene	NULL
are	NULL
measured	NULL
as	NULL
a	NULL
47-base-pair	NULL
transcript	NULL
,	NULL
whereas	NULL
properly	NULL
-	NULL
>	NULL
initiated	NULL
transcripts	NULL
from	NULL
the	NULL
transfected	NULL
gene	NULL
are	NULL
250	NULL
base	NULL
pairs	NULL
.	NULL

NS	NULL
,	NULL
nonstimulated	NULL
cells	NULL
;	NULL
S	NULL
,	NULL
cells	NULL
stimulated	NULL
for	NULL
5	NULL
hr	NULL
with	NULL
32	NULL
nM	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
and	NULL
2	NULL
uM	NULL
ionomycin	NULL
;	NULL
FK	NULL
,	NULL
1.2	NULL
nM	NULL
FK506	NULL
;	NULL
Rapa	NULL
,	NULL
550	NULL
nM	NULL
rapamycin	NULL
;	NULL
Markers	NULL
,	NULL
Msp	NULL
I-digested	NULL
pBR322	NULL
DNA	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Dose-response	NULL
curve	NULL
of	NULL
effects	NULL
of	NULL
FK506	NULL
and	NULL
rapamycin	NULL
on	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
NF-AT	NULL
,	NULL
measured	NULL
as	NULL
the	NULL
enzymatic	NULL
activity	NULL
of	NULL
B-galactosidase	NULL
transcribed	NULL
from	NULL
the	NULL
NFAT-Gal	NULL
construct	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
stimulated	NULL
as	NULL
in	NULL
B	NULL
.	NULL

(	NULL
D	NULL
)	NULL
FK506	NULL
partially	NULL
inhibits	NULL
the	NULL
development	NULL
of	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
NF-AT	NULL
,	NULL
and	NULL
rapamycin	NULL
reverses	NULL
the	NULL
effect	NULL
of	NULL
FK506	NULL
.	NULL

Jurkat	NULL
cells	NULL
,	NULL
5	NULL
x	NULL
10	NULL
``	NULL
for	NULL
each	NULL
condition	NULL
,	NULL
were	NULL
stimulated	NULL
for	NULL
5	NULL
hr	NULL
with	NULL
32	NULL
nM	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
and	NULL
2	NULL
uM	NULL
ionomycin	NULL
.	NULL

NF-AT	NULL
binding	NULL
activity	NULL
was	NULL
assayed	NULL
by	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
using	NULL
the	NULL
NF-AT	NULL
binding	NULL
site	NULL
as	NULL
a	NULL
probe	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Abbreviations	NULL
are	NULL
as	NULL
in	NULL
B	NULL
.	NULL

9234	NULL
Immunology	NULL
:	NULL
Bierer	NULL
et	NULL
al	NULL
.	NULL

the	NULL
predominant	NULL
cytosolic	NULL
binding	NULL
protein	NULL
for	NULL
FK	NULL
506	NULL
,	NULL
FKBP	NULL
,	NULL
was	NULL
isolated	NULL
and	NULL
shown	NULL
to	NULL
be	NULL
a	NULL
rotamase	NULL
(	NULL
7-9	NULL
)	NULL
.	NULL

FK	NULL
506	NULL
,	NULL
but	NULL
not	NULL
CsA	NULL
,	NULL
binds	NULL
FKBP	NULL
with	NULL
high	NULL
affinity	NULL
and	NULL
potently	NULL
inhibits	NULL
this	NULL
rotamase	NULL
activity	NULL
.	NULL

Recently	NULL
we	NULL
have	NULL
observed	NULL
that	NULL
FKBP	NULL
was	NULL
also	NULL
the	NULL
predominant	NULL
protein	NULL
isolated	NULL
with	NULL
a	NULL
rapamycin	NULL
affinity	NULL
column	NULL
(	NULL
H.	NULL
Fretz	NULL
,	NULL
M.	NULL
W.	NULL
Albers	NULL
,	NULL
R.F.S	NULL
.	NULL

,	NULL
A.	NULL
Galat	NULL
,	NULL
and	NULL
S.L.S	NULL
.	NULL

,	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

In	NULL
a	NULL
competitive	NULL
binding	NULL
assay	NULL
,	NULL
rapamycin	NULL
(	NULL
K4	NULL
=	NULL
0.2	NULL
nM	NULL
)	NULL
was	NULL
slightly	NULL
more	NULL
effective	NULL
than	NULL
FK506	NULL
(	NULL
K	NULL
,	NULL
=	NULL
0.4	NULL
nM	NULL
)	NULL
in	NULL
displacing	NULL
[	NULL
}	NULL
H	NULL
}	NULL
dihy-droFK506	NULL
from	NULL
recombinant	NULL
human	NULL
FKBP	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Both	NULL
rapamycin	NULL
(	NULL
K	NULL
;	NULL
=	NULL
0.2	NULL
nM	NULL
)	NULL
and	NULL
FK506	NULL
(	NULL
K	NULL
;	NULL
=	NULL
1.7	NULL
nM	NULL
;	NULL
ref	NULL
.	NULL

14	NULL
)	NULL
are	NULL
also	NULL
potent	NULL
rotamase	NULL
inhibitors	NULL
of	NULL
FKBP	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

DISCUSSION	NULL
We	NULL
have	NULL
confirmed	NULL
that	NULL
FK506	NULL
and	NULL
rapamycin	NULL
act	NULL
upon	NULL
distinct	NULL
T-cell	NULL
signal	NULL
transduction	NULL
pathways	NULL
and	NULL
inhibit	NULL
each	NULL
other	NULL
's	NULL
actions	NULL
.	NULL

FK506	NULL
inhibits	NULL
IL-2	NULL
production	NULL
and	NULL
activation-induced	NULL
apoptosis	NULL
in	NULL
a	NULL
constitutively	NULL
dividing	NULL
T-cell	NULL
line	NULL
;	NULL
rapamycin	NULL
reverses	NULL
the	NULL
actions	NULL
of	NULL
FK506	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
rapamycin	NULL
restores	NULL
NF-AT-dependent	NULL
transcriptional	NULL
activation	NULL
and	NULL
DNA	NULL
binding	NULL
inhibited	NULL
by	NULL
FK506	NULL
.	NULL

Although	NULL
rapamycin-induced	NULL
inhibition	NULL
of	NULL
lymphokine-dependent	NULL
proliferation	NULL
was	NULL
only	NULL
modest	NULL
(	NULL
30	NULL
%	NULL
,	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
FK506	NULL
consistently	NULL
reversed	NULL
this	NULL
inhibition	NULL
.	NULL

These	NULL
data	NULL
are	NULL
consistent	NULL
with	NULL
prior	NULL
studies	NULL
demonstrating	NULL
that	NULL
FK	NULL
506	NULL
reversed	NULL
the	NULL
suppressive	NULL
effect	NULL
of	NULL
rapamycin	NULL
(	NULL
40-60	NULL
%	NULL
)	NULL
on	NULL
the	NULL
stimulation	NULL
of	NULL
splenic	NULL
T	NULL
cells	NULL
with	NULL
IL-2	NULL
plus	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
13	NULL
)	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
rapamycin	NULL
does	NULL
not	NULL
inhibit	NULL
NF-AT-directed	NULL
transcriptional	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
further	NULL
supports	NULL
the	NULL
conclusion	NULL
that	NULL
FK506	NULL
and	NULL
rapamycin	NULL
affect	NULL
different	NULL
signal	NULL
transduction	NULL
pathways	NULL
.	NULL

Both	NULL
FK506	NULL
and	NULL
rapamycin	NULL
bind	NULL
to	NULL
and	NULL
inhibit	NULL
the	NULL
rotamase	NULL
activity	NULL
of	NULL
the	NULL
immunophilin	NULL
FKBP	NULL
.	NULL

A	NULL
common	NULL
binding	NULL
site	NULL
for	NULL
both	NULL
drugs	NULL
on	NULL
FKBP	NULL
has	NULL
been	NULL
determined	NULL
by	NULL
NMR	NULL
spectroscopic	NULL
studies	NULL
of	NULL
the	NULL
rapamycin-FKBP	NULL
and	NULL
FK506-FKBP	NULL
complexes	NULL
(	NULL
S.	NULL
W.	NULL
Michnick	NULL
,	NULL
M.	NULL
K.	NULL
Rosen	NULL
,	NULL
T.	NULL
J.	NULL
Wandless	NULL
,	NULL
and	NULL
S.L.S	NULL
.	NULL

,	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

The	NULL
concentration	NULL
required	NULL
for	NULL
reciprocal	NULL
inhibition	NULL
between	NULL
FK506	NULL
and	NULL
rapamycin	NULL
in	NULL
biological	NULL
assays	NULL
suggests	NULL
that	NULL
the	NULL
receptor	NULL
site	NULL
,	NULL
and	NULL
not	NULL
the	NULL
drug	NULL
,	NULL
is	NULL
in	NULL
excess	NULL
in	NULL
the	NULL
cell	NULL
.	NULL

This	NULL
is	NULL
readily	NULL
explained	NULL
by	NULL
the	NULL
abundance	NULL
of	NULL
the	NULL
immunophilin	NULL
FKBP	NULL
(	NULL
~5	NULL
nM	NULL
;	NULL
ref	NULL
.	NULL

38	NULL
)	NULL
,	NULL
which	NULL
acts	NULL
as	NULL
a	NULL
buffer	NULL
against	NULL
the	NULL
mutually	NULL
inhibitory	NULL
actions	NULL
of	NULL
the	NULL
two	NULL
drugs	NULL
.	NULL

The	NULL
concentration	NULL
of	NULL
the	NULL
antagonizing	NULL
agent	NULL
rises	NULL
to	NULL
sufficient	NULL
levels	NULL
to	NULL
displace	NULL
the	NULL
drug	NULL
effectively	NULL
from	NULL
its	NULL
biological	NULL
receptor	NULL
only	NULL
after	NULL
the	NULL
excess	NULL
FKBP	NULL
binding	NULL
sites	NULL
are	NULL
occupied	NULL
.	NULL

This	NULL
a	NULL
§y__	NULL
sss	NULL
m	NULL
moa	NULL
_	NULL
s	NULL
s	NULL
s	NULL
a	NULL
i	NULL
bss	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

FK506	NULL
reverses	NULL
the	NULL
inhibition	NULL
mediated	NULL
by	NULL
rapamycin	NULL
.	NULL

Rapamycin	NULL
inhibition	NULL
of	NULL
,	NULL
and	NULL
FK506	NULL
reversal	NULL
of	NULL
,	NULL
IL-2-dependent	NULL
proliferation	NULL
of	NULL
CTLL-20	NULL
is	NULL
shown	NULL
.	NULL

The	NULL
murine	NULL
IL-2-dependent	NULL
T-cell	NULL
line	NULL
CTLL-20	NULL
was	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
0.5	NULL
%	NULL
IL-2-containing	NULL
rat	NULL
culture	NULL
supernatant	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
rapamycin	NULL
or	NULL
FK506	NULL
at	NULL
the	NULL
indicated	NULL
concentrations	NULL
.	NULL

Proliferation	NULL
was	NULL
assessed	NULL
by	NULL
the	NULL
incorporation	NULL
of	NULL
[	NULL
'HIthymidine	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87	NULL
(	NULL
1990	NULL
)	NULL
0.5	NULL
ke	NULL
0.41	NULL
8	NULL
ao	NULL
A	NULL
°	NULL
a	NULL
o	NULL
0.37	NULL
®	NULL
A	NULL
a	NULL
A	NULL
A	NULL
E	NULL
0	NULL
o	NULL
t	NULL
&	NULL
o	NULL
*	NULL
0.2	NULL
a	NULL
°	NULL
&	NULL
m	NULL
A	NULL
A	NULL
j	NULL
o	NULL
dihydro	NULL
m	NULL
o	NULL
0	NULL
FK506	NULL
9.11	NULL
m	NULL
®	NULL
rapamycin	NULL
0.0	NULL
r	NULL
A	NULL
1	NULL
10	NULL
competitor	NULL
,	NULL
nM	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Competitive	NULL
binding	NULL
to	NULL
FKBP	NULL
.	NULL

The	NULL
binding	NULL
assay	NULL
measured	NULL
the	NULL
ability	NULL
of	NULL
FK506	NULL
(	NULL
K4	NULL
=	NULL
0.4	NULL
nM	NULL
)	NULL
,	NULL
rapamycin	NULL
(	NULL
K4	NULL
=	NULL
0.2	NULL
nM	NULL
)	NULL
,	NULL
and	NULL
dihydroFK506	NULL
(	NULL
K4	NULL
=	NULL
0.8	NULL
nM	NULL
)	NULL
to	NULL
displace	NULL
PH	NULL
}	NULL
dihydroFK506	NULL
from	NULL
FKBP	NULL
,	NULL
and	NULL
the	NULL
fraction	NULL
of	NULL
total	NULL
label	NULL
bound	NULL
is	NULL
shown	NULL
versus	NULL
total	NULL
competitor	NULL
concentration	NULL
.	NULL

Each	NULL
point	NULL
is	NULL
the	NULL
average	NULL
of	NULL
two	NULL
measurements	NULL
.	NULL

B	NULL
,	NULL
bound	NULL
;	NULL
T	NULL
,	NULL
bound	NULL
plus	NULL
free	NULL
,	NULL
or	NULL
total	NULL
.	NULL

concentration	NULL
dependence	NULL
and	NULL
the	NULL
above	NULL
analysis	NULL
also	NULL
strongly	NULL
suggest	NULL
that	NULL
the	NULL
immunophilin-drug	NULL
complex	NULL
is	NULL
the	NULL
biological	NULL
effector	NULL
.	NULL

This	NULL
conclusion	NULL
is	NULL
analogous	NULL
to	NULL
that	NULL
reached	NULL
by	NULL
Tropschug	NULL
et	NULL
al	NULL
.	NULL

(	NULL
39	NULL
)	NULL
in	NULL
their	NULL
study	NULL
of	NULL
mutant	NULL
strains	NULL
of	NULL
Neurospora	NULL
crassa	NULL
and	NULL
Saccharomyces	NULL
cerevisiae	NULL
that	NULL
are	NULL
resistant	NULL
to	NULL
CsA	NULL
.	NULL

These	NULL
mutated	NULL
organisms	NULL
either	NULL
lost	NULL
their	NULL
ability	NULL
to	NULL
produce	NULL
the	NULL
CsA	NULL
binding	NULL
immunophilin	NULL
CyP	NULL
,	NULL
or	NULL
,	NULL
if	NULL
CyP	NULL
was	NULL
produced	NULL
,	NULL
it	NULL
no	NULL
longer	NULL
bound	NULL
CsA	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
was	NULL
concluded	NULL
that	NULL
the	NULL
immunophilin-drug	NULL
complex	NULL
was	NULL
responsible	NULL
for	NULL
the	NULL
toxic	NULL
actions	NULL
of	NULL
the	NULL
drug	NULL
on	NULL
these	NULL
organisms	NULL
.	NULL

Invoking	NULL
the	NULL
immunophilin-drug	NULL
complex	NULL
as	NULL
the	NULL
biological	NULL
effector	NULL
addresses	NULL
the	NULL
issue	NULL
of	NULL
how	NULL
the	NULL
ubiquitous	NULL
CyP	NULL
and	NULL
FKBP	NULL
immunophilins	NULL
could	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
T-cell	NULL
activa-	NULL
C	NULL
0.084	NULL
0.061	NULL
)	NULL
FA	NULL
0.041	NULL
x8	NULL
0.024	NULL
[	NULL
FKBP	NULL
]	NULL
=	NULL
36	NULL
nM	NULL
0	NULL
r	NULL
r	NULL
0	NULL
50	NULL
100	NULL
[	NULL
rapamycin	NULL
]	NULL
(	NULL
nM	NULL
)	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Inhibition	NULL
of	NULL
rotamase	NULL
activity	NULL
of	NULL
FKBP	NULL
by	NULL
rapamycin	NULL
.	NULL

The	NULL
first-order	NULL
rate	NULL
constant	NULL
for	NULL
cis	NULL
-	NULL
trans	NULL
isomerization	NULL
of	NULL
the	NULL
test	NULL
substrate	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
36	NULL
nM	NULL
FKBP	NULL
is	NULL
plotted	NULL
against	NULL
drug	NULL
concentration	NULL
.	NULL

Two	NULL
points	NULL
are	NULL
shown	NULL
for	NULL
each	NULL
drug	NULL
concentration	NULL
,	NULL
and	NULL
five	NULL
points	NULL
are	NULL
shown	NULL
for	NULL
the	NULL
control	NULL
(	NULL
no	NULL
drug	NULL
)	NULL
.	NULL

The	NULL
curve	NULL
is	NULL
the	NULL
best-fit	NULL
binding	NULL
model	NULL
.	NULL

The	NULL
horizontal	NULL
asymptote	NULL
represents	NULL
the	NULL
rate	NULL
of	NULL
isomerization	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
catalysis	NULL
(	NULL
k	NULL
=	NULL
0.0074	NULL
s~1	NULL
)	NULL
.	NULL

obs	NULL
,	NULL
Observed	NULL
.	NULL

Immunology	NULL
:	NULL
Bierer	NULL
et	NULL
al	NULL
.	NULL

tion	NULL
process	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
these	NULL
proteins	NULL
have	NULL
a	NULL
more	NULL
general	NULL
cellular	NULL
function	NULL
,	NULL
perhaps	NULL
assisting	NULL
in	NULL
protein	NULL
folding	NULL
in	NULL
vivo	NULL
(	NULL
as	NULL
foldases	NULL
)	NULL
.	NULL

Only	NULL
when	NULL
the	NULL
immunophilin	NULL
combines	NULL
with	NULL
its	NULL
immunosuppressive	NULL
ligand	NULL
does	NULL
it	NULL
inhibit	NULL
T-cell	NULL
activation	NULL
.	NULL

We	NULL
suggest	NULL
that	NULL
the	NULL
cellular	NULL
immunophilin	NULL
recep-tor	NULL
,	NULL
bound	NULL
to	NULL
either	NULL
rapamycin	NULL
or	NULL
FK506	NULL
,	NULL
may	NULL
interact	NULL
with	NULL
different	NULL
molecules	NULL
in	NULL
separable	NULL
pathways	NULL
of	NULL
T-cell	NULL
activation	NULL
.	NULL

The	NULL
above	NULL
hypothesis	NULL
raises	NULL
the	NULL
question	NULL
as	NULL
to	NULL
whether	NULL
the	NULL
immunosuppressive	NULL
drugs	NULL
may	NULL
mimic	NULL
the	NULL
actions	NULL
of	NULL
endogenous	NULL
immunophilin	NULL
ligands	NULL
.	NULL

If	NULL
so	NULL
,	NULL
the	NULL
active	NULL
site	NULL
of	NULL
a	NULL
rotamase	NULL
enzyme	NULL
would	NULL
also	NULL
serve	NULL
as	NULL
a	NULL
regulatory	NULL
binding	NULL
site	NULL
for	NULL
use	NULL
in	NULL
immune	NULL
modulation	NULL
.	NULL

Rotamase	NULL
inhibition	NULL
should	NULL
not	NULL
necessarily	NULL
correlate	NULL
with	NULL
immunosuppression	NULL
,	NULL
as	NULL
effective	NULL
drug	NULL
concentrations	NULL
of	NULL
0.5	NULL
nM	NULL
would	NULL
only	NULL
inhibit	NULL
=10	NULL
%	NULL
of	NULL
the	NULL
total	NULL
enzyme	NULL
present	NULL
in	NULL
the	NULL
cell	NULL
.	NULL

Indeed	NULL
,	NULL
both	NULL
rapamycin	NULL
and	NULL
FK	NULL
506	NULL
inhibit	NULL
the	NULL
rotamase	NULL
activity	NULL
of	NULL
FKBP	NULL
but	NULL
have	NULL
different	NULL
effects	NULL
on	NULL
T-cell	NULL
activation	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
inhibition	NULL
of	NULL
the	NULL
rotamase	NULL
activity	NULL
of	NULL
FKBP	NULL
assessed	NULL
in	NULL
vitro	NULL
can	NULL
not	NULL
explain	NULL
the	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
these	NULL
compounds	NULL
,	NULL
as	NULL
we	NULL
have	NULL
recently	NULL
shown	NULL
(	NULL
40	NULL
)	NULL
.	NULL

FKBP	NULL
is	NULL
the	NULL
predominant	NULL
protein	NULL
isolated	NULL
from	NULL
both	NULL
FK506	NULL
affinity	NULL
and	NULL
rapamycin	NULL
affinity	NULL
matrices	NULL
.	NULL

From	NULL
both	NULL
matrices	NULL
,	NULL
however	NULL
,	NULL
other	NULL
,	NULL
low-abundance	NULL
FK506	NULL
and	NULL
rapamycin	NULL
binding	NULL
proteins	NULL
have	NULL
been	NULL
eluted	NULL
and	NULL
characterized	NULL
(	NULL
H.	NULL
Fretz	NULL
,	NULL
M.	NULL
W.	NULL
Albers	NULL
,	NULL
R.F.S	NULL
.	NULL

,	NULL
A.	NULL
Galat	NULL
,	NULL
and	NULL
S.L.S	NULL
.	NULL

,	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
possibility	NULL
also	NULL
exists	NULL
that	NULL
the	NULL
common	NULL
binding	NULL
site	NULL
implied	NULL
by	NULL
the	NULL
mechanistic	NULL
studies	NULL
reported	NULL
herein	NULL
and	NULL
elsewhere	NULL
(	NULL
13	NULL
)	NULL
is	NULL
found	NULL
on	NULL
separate	NULL
immunophilin	NULL
proteins	NULL
.	NULL

In	NULL
this	NULL
circumstance	NULL
,	NULL
the	NULL
high	NULL
affinity	NULL
of	NULL
FK506	NULL
and	NULL
rapamycin	NULL
for	NULL
FKBP	NULL
and	NULL
the	NULL
high	NULL
abundance	NULL
of	NULL
FKBP	NULL
require	NULL
that	NULL
an	NULL
even	NULL
higher	NULL
affinity	NULL
for	NULL
drug	NULL
must	NULL
exist	NULL
with	NULL
the	NULL
minor	NULL
immunophilins	NULL
or	NULL
that	NULL
the	NULL
intrinsic	NULL
activity	NULL
of	NULL
the	NULL
drugs	NULL
is	NULL
actually	NULL
much	NULL
greater	NULL
than	NULL
the	NULL
apparent	NULL
activity	NULL
measured	NULL
experimentally	NULL
.	NULL

In	NULL
either	NULL
situa-tion	NULL
,	NULL
the	NULL
low-abundance	NULL
immunophilin	NULL
must	NULL
compete	NULL
with	NULL
FKBP	NULL
for	NULL
drug	NULL
and	NULL
thus	NULL
overcome	NULL
the	NULL
buffer	NULL
effect	NULL
seen	NULL
in	NULL
the	NULL
mutual	NULL
inhibition	NULL
studies	NULL
.	NULL

These	NULL
data	NULL
support	NULL
several	NULL
conclusions	NULL
.	NULL

Neither	NULL
mere	NULL
binding	NULL
to	NULL
FKBP	NULL
nor	NULL
rotamase	NULL
inhibition	NULL
can	NULL
explain	NULL
the	NULL
effects	NULL
of	NULL
FK506	NULL
and	NULL
rapamycin	NULL
on	NULL
T-cell	NULL
activation	NULL
.	NULL

The	NULL
high	NULL
affinity	NULL
of	NULL
FKBP	NULL
for	NULL
both	NULL
agents	NULL
makes	NULL
it	NULL
an	NULL
attractive	NULL
,	NULL
but	NULL
not	NULL
unique	NULL
,	NULL
candidate	NULL
for	NULL
the	NULL
relevant	NULL
in	NULL
vivo	NULL
receptor	NULL
of	NULL
both	NULL
drugs	NULL
.	NULL

This	NULL
apparently	NULL
common	NULL
receptor	NULL
site	NULL
must	NULL
be	NULL
involved	NULL
in	NULL
regulating	NULL
at	NULL
least	NULL
two	NULL
different	NULL
signal	NULL
transduction	NULL
pathways	NULL
,	NULL
one	NULL
initiated	NULL
at	NULL
the	NULL
T-cell	NULL
receptor	NULL
and	NULL
resulting	NULL
in	NULL
lymphokine	NULL
production	NULL
and	NULL
the	NULL
other	NULL
,	NULL
perhaps	NULL
initiated	NULL
at	NULL
a	NULL
lymphokine	NULL
receptor	NULL
and	NULL
resulting	NULL
in	NULL
cellular	NULL
proliferation	NULL
.	NULL

A	NULL
comparison	NULL
of	NULL
the	NULL
FK506	NULL
and	NULL
rapamycin	NULL
structures	NULL
suggests	NULL
that	NULL
they	NULL
consist	NULL
of	NULL
a	NULL
common	NULL
receptor-binding	NULL
domain	NULL
(	NULL
recently	NULL
suggested	NULL
to	NULL
mimic	NULL
a	NULL
twisted	NULL
leucyl-prolyl	NULL
amide	NULL
bond	NULL
)	NULL
(	NULL
27	NULL
)	NULL
and	NULL
unique	NULL
effector	NULL
domains	NULL
that	NULL
are	NULL
responsible	NULL
for	NULL
the	NULL
difference	NULL
in	NULL
their	NULL
activities	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
the	NULL
two	NULL
drugs	NULL
would	NULL
then	NULL
arise	NULL
from	NULL
interactions	NULL
of	NULL
their	NULL
respective	NULL
receptor	NULL
complexes	NULL
with	NULL
different	NULL
target	NULL
mole	NULL
cules	NULL
.	NULL

We	NULL
thank	NULL
P.	NULL
Mather	NULL
,	NULL
D.	NULL
Naab	NULL
,	NULL
and	NULL
M.	NULL
McCutchin	NULL
for	NULL
technical	NULL
assistance	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
CA	NULL
39542	NULL
,	NULL
CA	NULL
42509	NULL
,	NULL
CA	NULL
39612	NULL
,	NULL
HL33942	NULL
,	NULL
and	NULL
GM-38627	NULL
;	NULL
the	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
;	NULL
and	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Dyson	NULL
Foundation	NULL
.	NULL

B.E.B	NULL
.	NULL

is	NULL
the	NULL
recipient	NULL
of	NULL
a	NULL
McDonnell	NULL
Scholar	NULL
Award	NULL
from	NULL
the	NULL
James	NULL
S.	NULL
McDonnell	NULL
Foundation	NULL
and	NULL
of	NULL
a	NULL
Clinician-Scientist	NULL
Award	NULL
from	NULL
the	NULL
American	NULL
Heart	NULL
Association	NULL
.	NULL

P.S.M	NULL
.	NULL

is	NULL
the	NULL
recipient	NULL
of	NULL
financial	NULL
support	NULL
from	NULL
the	NULL
Paolo	NULL
Foundation	NULL
.	NULL

w	NULL
Dr	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87	NULL
(	NULL
1990	NULL
)	NULL
9235	NULL
Shevach	NULL
,	NULL
E.	NULL
M.	NULL
(	NULL
1985	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

3	NULL
,	NULL
397-423	NULL
.	NULL

Thomson	NULL
,	NULL
A.	NULL
W.	NULL
(	NULL
1989	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
10	NULL
,	NULL
6-10	NULL
.	NULL

Starzl	NULL
,	NULL
T.	NULL
,	NULL
Fung	NULL
,	NULL
J.	NULL
,	NULL
Venkataramman	NULL
,	NULL
R.	NULL
,	NULL
Todo	NULL
,	NULL
S.	NULL
,	NULL
Demetris	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

&	NULL
Jain	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Lancet	NULL
i	NULL
,	NULL
1000-1004	NULL
.	NULL

Handschumacher	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Harding	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
Rice	NULL
,	NULL
J.	NULL
,	NULL
Drugge	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

&	NULL
Speicher	NULL
,	NULL
D.	NULL
W.	NULL
(	NULL
1984	NULL
)	NULL
Science	NULL
226	NULL
,	NULL
544-546	NULL
.	NULL

Takahashi	NULL
,	NULL
N.	NULL
,	NULL
Hayano	NULL
,	NULL
T.	NULL
&	NULL
Suzuki	NULL
,	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
337	NULL
,	NULL
473-475	NULL
.	NULL

Fischer	NULL
,	NULL
G.	NULL
,	NULL
Wittmann-Liebold	NULL
,	NULL
B.	NULL
,	NULL
Lang	NULL
,	NULL
K.	NULL
,	NULL
Kiefhaber	NULL
,	NULL
T.	NULL
&	NULL
Schmid	NULL
,	NULL
F.	NULL
X	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
337	NULL
,	NULL
476-478	NULL
.	NULL

Harding	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
Galat	NULL
,	NULL
A.	NULL
,	NULL
Uehling	NULL
,	NULL
D.	NULL
E.	NULL
&	NULL
Schreiber	NULL
,	NULL
S.	NULL
L.	NULL
(	NULL
1989	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
341	NULL
,	NULL
758-760	NULL
.	NULL

Siekierka	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Hung	NULL
,	NULL
S.	NULL
H.	NULL
Y.	NULL
,	NULL
Poe	NULL
,	NULL
M.	NULL
,	NULL
Lin	NULL
,	NULL
C.	NULL
S.	NULL
&	NULL
Sigal	NULL
,	NULL
N.	NULL
H.	NULL
(	NULL
1989	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
341	NULL
,	NULL
755-757	NULL
.	NULL

Standaert	NULL
,	NULL
R.	NULL
F.	NULL
,	NULL
Galat	NULL
,	NULL
A.	NULL
,	NULL
Verdine	NULL
,	NULL
G.	NULL
L.	NULL
&	NULL
Schreiber	NULL
,	NULL
S.	NULL
L.	NULL
(	NULL
1990	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
346	NULL
,	NULL
671-674	NULL
.	NULL

Maki	NULL
,	NULL
N.	NULL
,	NULL
Sekiguchi	NULL
,	NULL
F.	NULL
,	NULL
Nishimaki	NULL
,	NULL
J.	NULL
,	NULL
Miwa	NULL
,	NULL
K.	NULL
,	NULL
Hayano	NULL
,	NULL
T.	NULL
,	NULL
Takahashi	NULL
,	NULL
N.	NULL
&	NULL
Suzuki	NULL
,	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad..Sci	NULL
.	NULL

USA	NULL
87	NULL
,	NULL
5440-5443	NULL
.	NULL

Sehgal	NULL
,	NULL
S.	NULL
N.	NULL
,	NULL
Baker	NULL
,	NULL
H.	NULL
&	NULL
Vezina	NULL
,	NULL
C.	NULL
(	NULL
1975	NULL
)	NULL
J.	NULL
Antibiot	NULL
.	NULL

28	NULL
,	NULL
727-742	NULL
.	NULL

Dumont	NULL
,	NULL
F.	NULL
J.	NULL
,	NULL
Staruch	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Koprak	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Melino	NULL
,	NULL
M.	NULL
R.	NULL
&	NULL
Sigal	NULL
,	NULL
N.	NULL
H.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

144	NULL
,	NULL
251-258	NULL
.	NULL

Dumont	NULL
,	NULL
F.	NULL
J.	NULL
,	NULL
Melino	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Staruch	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Koprak	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Fischer	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

&	NULL
Sigal	NULL
,	NULL
N.	NULL
H.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

144	NULL
,	NULL
1418-1424	NULL
.	NULL

Harrison	NULL
,	NULL
R.	NULL
K.	NULL
&	NULL
Stein	NULL
,	NULL
R.	NULL
L.	NULL
(	NULL
1990	NULL
)	NULL
Biochemistry	NULL
29	NULL
,	NULL
3813-3816	NULL
.	NULL

Bierer	NULL
,	NULL
B.	NULL
E.	NULL
,	NULL
Peterson	NULL
,	NULL
A.	NULL
,	NULL
Barbosa	NULL
,	NULL
J.	NULL
,	NULL
Seed	NULL
,	NULL
B	NULL
.	NULL

&	NULL
Burakoff	NULL
,	NULL
S.	NULL
F.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85	NULL
,	NULL
1194-1198	NULL
.	NULL

Leo	NULL
,	NULL
C.	NULL
,	NULL
Foo	NULL
,	NULL
M.	NULL
,	NULL
Sachs	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
Samuelson	NULL
,	NULL
L.	NULL
E.	NULL
&	NULL
Bluestone	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84	NULL
,	NULL
1374-1378	NULL
.	NULL

Shi	NULL
,	NULL
Y.	NULL
,	NULL
Sahai	NULL
,	NULL
B.	NULL
M.	NULL
&	NULL
Green	NULL
,	NULL
D.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
339	NULL
,	NULL
625-627	NULL
.	NULL

Fiering	NULL
,	NULL
S.	NULL
,	NULL
Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Nolan	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
&	NULL
Herzenberg	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

,	NULL
in	NULL
press	NULL
.	NULL

Nolan	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Fiering	NULL
,	NULL
S.	NULL
,	NULL
Nicolas	NULL
,	NULL
J.	NULL
F.	NULL
&	NULL
Herzenberg	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85	NULL
,	NULL
2603-2607	NULL
.	NULL

Verweij	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
Guidos	NULL
,	NULL
C.	NULL
&	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
in	NULL
press	NULL
.	NULL

Melton	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Krieg	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Rebagliat	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Maniatis	NULL
,	NULL
T.	NULL
,	NULL
Zinn	NULL
,	NULL
K.	NULL
&	NULL
Green	NULL
,	NULL
M.	NULL
R.	NULL
(	NULL
1984	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

12	NULL
,	NULL
7035-7056	NULL
.	NULL

Courtois	NULL
,	NULL
G.	NULL
,	NULL
Morgan	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Campbel	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Fourel	NULL
,	NULL
G.	NULL
&	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1987	NULL
)	NULL
Science	NULL
238	NULL
,	NULL
688-692	NULL
.	NULL

Bradford	NULL
,	NULL
M.	NULL
M.	NULL
(	NULL
1976	NULL
)	NULL
Anal	NULL
.	NULL

Biochem	NULL
.	NULL

72	NULL
,	NULL
248-254	NULL
.	NULL

Garner	NULL
,	NULL
M.	NULL
M.	NULL
&	NULL
Revzin	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

9	NULL
,	NULL
3047-3060	NULL
.	NULL

Fried	NULL
,	NULL
M.	NULL
&	NULL
Crothers	NULL
,	NULL
D.	NULL
M.	NULL
(	NULL
1981	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

9	NULL
,	NULL
6505-6525	NULL
.	NULL

Munson	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

&	NULL
Rodbard	NULL
,	NULL
D.	NULL
(	NULL
1980	NULL
)	NULL
Anal	NULL
.	NULL

Biochem	NULL
.	NULL

107	NULL
,	NULL
220-239	NULL
.	NULL

Albers	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
Walsh	NULL
,	NULL
C.	NULL
T.	NULL
&	NULL
Schreiber	NULL
,	NULL
S.	NULL
L.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Org	NULL
.	NULL

Chem	NULL
.	NULL

55	NULL
,	NULL
4984-4986	NULL
.	NULL

Swain	NULL
,	NULL
C.	NULL
G.	NULL
,	NULL
Swain	NULL
,	NULL
M.	NULL
S.	NULL
&	NULL
Berg	NULL
,	NULL
L.	NULL
F.	NULL
(	NULL
1980	NULL
)	NULL
J.	NULL
Chem	NULL
.	NULL

Inf	NULL
.	NULL

Comput	NULL
.	NULL

Sci	NULL
.	NULL

20	NULL
,	NULL
47-51	NULL
.	NULL

Williams	NULL
,	NULL
J.	NULL
W.	NULL
&	NULL
Morrison	NULL
,	NULL
J.	NULL
F.	NULL
(	NULL
1979	NULL
)	NULL
Methods	NULL
Enzymol	NULL
.	NULL

63	NULL
,	NULL
437-467	NULL
.	NULL

Mercep	NULL
,	NULL
M.	NULL
,	NULL
Noguchi	NULL
,	NULL
P.	NULL
D.	NULL
&	NULL
Ashwell	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

142	NULL
,	NULL
4085-4092	NULL
.	NULL

Tocci	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Matkovich	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Collier	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Kwok	NULL
,	NULL
P.	NULL
,	NULL
Dumont	NULL
,	NULL
F.	NULL
,	NULL
Lin	NULL
,	NULL
S.	NULL
,	NULL
Degudicibus	NULL
,	NULL
S.	NULL
,	NULL
Siekierka	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Chin	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Hutchin-son	NULL
,	NULL
N.	NULL
I	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

143	NULL
,	NULL
718-726	NULL
.	NULL

Bierer	NULL
,	NULL
B.	NULL
E.	NULL
,	NULL
Schreiber	NULL
,	NULL
S.	NULL
L.	NULL
&	NULL
Burakoff	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Transplantation	NULL
49	NULL
,	NULL
1168-1170	NULL
.	NULL

Shaw	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Utz	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Toole	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Emmel	NULL
,	NULL
E.	NULL
A	NULL
.	NULL

&	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Science	NULL
241	NULL
,	NULL
202-205	NULL
.	NULL

Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Shaw	NULL
,	NULL
J.-P.	NULL
,	NULL
Bush	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Replogle	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Bela-gaje	NULL
,	NULL
R.	NULL
&	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8	NULL
,	NULL
1715-1724	NULL
.	NULL

Serfling	NULL
,	NULL
E.	NULL
,	NULL
Barthelmas	NULL
,	NULL
R.	NULL
,	NULL
Pfeuffer	NULL
,	NULL
I.	NULL
,	NULL
Schenk	NULL
,	NULL
B.	NULL
,	NULL
Zarius	NULL
,	NULL
S.	NULL
,	NULL
Swoboda	NULL
,	NULL
R.	NULL
,	NULL
Mercurio	NULL
,	NULL
F.	NULL
&	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

8	NULL
,	NULL
465-473	NULL
.	NULL

Fujita	NULL
,	NULL
T.	NULL
,	NULL
Shilbuya	NULL
,	NULL
H.	NULL
,	NULL
Ohashi	NULL
,	NULL
T.	NULL
,	NULL
Yamanishi	NULL
,	NULL
K.	NULL
&	NULL
Taniguchi	NULL
,	NULL
T.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
46	NULL
,	NULL
401-405	NULL
.	NULL

Emmel	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Verweij	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Higgins	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Lacy	NULL
,	NULL
E.	NULL
&	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
246	NULL
,	NULL
1617-1620	NULL
.	NULL

Siekierka	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Staruch	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Hung	NULL
,	NULL
S.	NULL
H.	NULL
Y	NULL
.	NULL

&	NULL
Sigal	NULL
,	NULL
N.	NULL
H.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

143	NULL
,	NULL
1580-1583	NULL
.	NULL

Tropschug	NULL
,	NULL
M.	NULL
,	NULL
Barthelmess	NULL
,	NULL
I	NULL
.	NULL

B	NULL
.	NULL

&	NULL
Neuper	NULL
,	NULL
W.	NULL
(	NULL
1989	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
342	NULL
,	NULL
953-955	NULL
.	NULL

Bierer	NULL
,	NULL
B.	NULL
E.	NULL
,	NULL
Somers	NULL
,	NULL
P.	NULL
K.	NULL
,	NULL
Wandless	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
Burakoff	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

&	NULL
Schreiber	NULL
,	NULL
S.	NULL
L.	NULL
(	NULL
1990	NULL
)	NULL
Science	NULL
250	NULL
,	NULL
556-559	NULL
.	NULL

